日本語のみで絞り込む
Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries.
Eisai is a research-based human health care company that discovers, develops and markets phamaceutical products internationally. Learn more about Eisai ...
We are a global leading research-based pharmaceutical company with operations in Asia, Australia, Europe, the Middle East, Latin America, New Zealand and the ...
【企業深層研究】エーザイ（下） エーザイの株価が冴えない。昨年来の株価は最高値が2023年6月の1万590円。以後はほぼ右肩下がり。8月2日に行った24年4～6月期の四半期決算では売上収益は1890億円で、前年同期比マイ...
日刊ゲンダイDIGITAL-
2024年10月2日（水）の日経平均株価をはじめ、日経平均寄与度の上位と下位銘柄、業種別騰落ランキング、東証プライム市場に上場している個別株式の騰落率ランキングなどをお伝えします。10月2日の日経平均株価は終日...
THE GOLD ONLINE（ゴールドオンライン）-
Eisai Co., Ltd is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and ...
Eisai Patient Support (EPS) provides information and resources to help patients afford the cost of LEQEMBI.
Eisai Innovation, Inc. is an investment entity formed to add cutting-edge technologies, drug modalities and digital healthcare solutions into the Eisai ...
Video Library: Share Videos of Eisai's Activities Including Initiatives for Improving Access to Medicines.
Eisai
Keep up to date with Webinars and Events relevant to your expertise and stay on top of the latest Clinical Studies, Developments about HI-Eisai and more by ...
Eisai Medical provides a variety of resources within the oncology and neurology treatment landscapes for HCPs.